Fabrice Egros has Been Appointed COO, Pharmaceutical Director and Board Member of NovaMedica, a Novel Pharmaceutical Company

Fabrice Egros has Been Appointed COO, Pharmaceutical Director and Board Member of NovaMedica, a Novel Pharmaceutical Company

<0> NovaMedicaElena Pochesneva, +7-495-545-39-12Director of public relations </0>

Fabrice Egros was appointed as COO, Pharmaceutical Director and board memberof NovaMedica, a novel Russian pharmaceutical company, which was established within the frameworks of the joint project between RUSNANO and the American venture fund Domain Associates.

The partnership involves joint investment in advanced medical technologies and late stage innovative drugs for their development, manufacture and commercialization, including the creation of a GMP production facility in Russia.

Mr. Egros has more than 20 years of international experience of work in the pharmaceutical industry. Prior to coming to NovaMedica he held managerial positions at Xanodyne, UCB (in Belgium, the USA and Japan). Fabrice also worked in others pharmaceutical companies, as Parke-Davis/Warner Lambert in Germany and the USA, Sanofi-Aventis in Japan and the USA. His responsibilities have encompassed Clinical development, marketing, market access, sales, Business development and general management functions Fabrice received his Pharm D and Ph.D in pharmaceutical sciences degrees at Chatenay Malabry University (Paris, France), a diploma in business administration from Schiller International University (Dunedin, Florida, USA). Besides that he studied Advanced Management Program at Harvard University (Cambridge, Massachusetts, USA).

“We have set ourselves the non-negotiable objective of building a Russian company that will be driven and inspired by the very best of international best practice in all facets of its operations and values - from day one. We also have ambitious and far-reaching plans to pursue joint business development activities with the most innovative Western players in the pharmaceuticals and life sciences space. For both of these reasons I am delighted that we have Fabrice Egros on board as our COO – he is a highly experienced life sciences senior executive with successful exposure to pharma markets across the globe,” said , NovaMedica CEO.

“Now I see my top priority in the creation of a great team of globally experienced life sciences industry talents from R&D, CMC, regulatory, business development, marketing and sales, to create the next generation life science company in Russia,” said .

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.